Sullivan Christopher Ryan
Avalo Therapeutics, Inc. · Chief Financial Officer
Sullivan Christopher Ryan is listed in filings as Chief Financial Officer at Avalo Therapeutics, Inc.. This profile follows SEC Form 4 activity through May 26, 2026, including sale activity. Recent filings connect the profile to Avalo Therapeutics, Inc. (AVTX). The current snapshot covers public activity from Aug 14, 2024 to May 26, 2026. Reported amounts are shown as $448.8K to $377.9K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.
History Trades
| Company | Value | Action | Price | Last Price |
|---|---|---|---|---|
| $257k13.8k shares | SellMay 6, 2026 | $18.55 | $17.88 | |
| $238k12.3k shares | SellMay 6, 2026 | $19.28 | $17.88 | |
| $201k8.9k shares | SellMay 6, 2026 | $22.57 | $17.88 | |
| $197k9.2k shares | SellMay 6, 2026 | $21.37 | $17.88 | |
| $56k2.7k shares | SellMay 6, 2026 | $20.76 | $17.88 | |
| $112k8.5k shares | SellApr 30, 2026 | $13.23 | $17.88 | |
| $111k8.5k shares | SellApr 29, 2026 | $13.09 | $17.88 | |
| $106k6.2k shares | SellApr 2, 2026 | $17.02 | $17.88 | |
| $31k1.8k shares | SellApr 2, 2026 | $17.57 | $17.88 | |
| $126k7.5k shares | SellApr 1, 2026 | $16.83 | $17.88 | |
| $7.9k500 shares | SellApr 1, 2026 | $15.86 | $17.88 |